A multicenter, phase II study (IFCT 1703-R2D2 trial) enrolled HER2-mutated advanced NSCLC patients progressing after platinum-based treatment and evaluated the efficacy and safety of triple therapy with trastuzumab, pertuzumab, and docetaxel (49). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.